



Acquired resistance in pancreatic cancer: characterization and exploration of actionable targets of a multifactorial disease

Bergonzini, C.

Citation

Bergonzini, C. (2026, January 27). *Acquired resistance in pancreatic cancer: characterization and exploration of actionable targets of a multifactorial disease*. Retrieved from <https://hdl.handle.net/1887/4289790>

Version: Publisher's Version

[Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

License: <https://hdl.handle.net/1887/4289790>

Note: To cite this publication please use the final published version (if applicable).

Chapter 2

ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells

Cecilia Bergonzini^{1†}, Alessandro Gregori^{2,3†}, Tessa M.S. Hagens¹, Vera E. van der Noord¹, Bob van de Water¹, Annelien J.M. Zweemer¹, Bircan Coban¹, Mjriam Capula^{3,4}, Giulia Mantini³, Asia Botto⁵, Francesco Finamore⁵, Ingrid Garajova⁶, Liam A. McDonnell⁵, Thomas Schmidt², Elisa Giovannetti^{3,4,*}, Erik H.J. Danen^{1,*}

¹ Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands

² Physics of Life Processes, Leiden Institute of Physics, Leiden University, Leiden, The Netherlands

³ Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU University, Amsterdam, The Netherlands

⁴ Cancer Pharmacology Lab, Fondazione Pisana per la Scienza, San Giuliano, Pisa, Italy

⁵ Proteomics and Metabolomics Lab, Fondazione Pisana per la Scienza, San Giuliano, Pisa, Italy

⁶ Medical Oncology Unit, University Hospital of Parma, Parma, Italy

†These authors contributed equally to this work and share first authorship

Published in *Experimental and Clinical Cancer Research* (2023)

Chapter 2

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of cancer and the chemotherapies such as gemcitabine/nab-paclitaxel are confronted with intrinsic or acquired resistance. The aim of this study was to investigate mechanisms underlying paclitaxel resistance in PDAC and explore strategies to overcome it.

Methods: Three paclitaxel (PR) and gemcitabine resistant (GR) PDAC models were established. Transcriptomics and proteomics were used to identify conserved mechanisms of drug resistance. Genetic and pharmacological approaches were used to overcome paclitaxel resistance.

Results: Upregulation of ABCB1 through locus amplification was identified as a conserved feature unique to PR cells. ABCB1 was not affected in any of the GR models and no cross resistance was observed. The ABCB1 inhibitor verapamil or siRNA-mediated ABCB1 depletion sensitized PR cells to paclitaxel and prevented efflux of ABCB1 substrates in all models. ABCB1 expression was associated with a trend towards shorter survival in patients who had received gemcitabine/nab-paclitaxel treatment. A pharmacological screen identified known and novel kinase inhibitors that attenuate efflux of ABCB1 substrates and sensitize PR PDAC cells to paclitaxel.

Conclusion: Upregulation of ABCB1 through locus amplification represents a novel, conserved mechanism of PDAC paclitaxel resistance. Kinase inhibitors identified in this study can be further (pre) clinically explored as therapeutic strategies to overcome paclitaxel resistance in PDAC.

Keywords: Pancreatic cancer, Paclitaxel resistance, ABCB1, Kinase-inhibitors

Background

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide¹, with a 5-year overall-survival reached in only 10% of patients². This poor prognosis is due to a lack of early biomarkers, limited therapeutic options, and inherent or acquired chemoresistance^{3, 4}. Currently, surgical resection is the only curative option for patients diagnosed with PDAC but less than 20% are diagnosed at an early stage and therefore eligible for surgery. In all other cases (i.e., advanced PDAC), chemotherapy using FOLFIRINOX or gemcitabine plus nab-paclitaxel are the only treatment options^{5, 6}. Unfortunately, these chemotherapy regimens increase survival up to 13 months at most, largely due to development of chemoresistance. So far, immunotherapy has not been successful for PDAC patients and new therapies under investigation targeting the tumor or the tumor microenvironment have not reached the clinic⁷⁻⁹. Therefore, identifying strategies to combat PDAC resistance to currently used chemotherapies is of crucial importance.

Gemcitabine is a cytotoxic DNA-intercalating drug, which arrests aberrant cell proliferation. Chemoresistance to gemcitabine in PDAC has been extensively studied and reported to be multifactorial¹⁰. On the other hand, paclitaxel is a microtubule-stabilizing drug that impedes cell division leading to replication errors and cell death. Paclitaxel also potentiates gemcitabine efficacy by increasing intratumor uptake and inhibiting its inactivation by catabolizing enzymes^{10, 11}. Mechanisms underlying paclitaxel resistance in PDAC are poorly understood^{12, 13}. Three studies have investigated paclitaxel resistance in PDAC, reporting that it involves metabolic adaptation¹⁴, sustained c-MYC activation¹⁵, and expression of orexin receptor type 1¹⁶.

ATP-binding cassette (ABC) transporters are responsible for active transport of many substrates, including cytotoxic drugs, across the cell membrane towards the extracellular space. ABC transporters are therefore known as multidrug resistance pumps^{13, 17}. The ABC family consists of 49 members, among which ABCB1 (also known as MDR1 or P-glycoprotein, P-gp) has been extensively studied in cancer. Overexpression of ABCB1 can mediate paclitaxel resistance in different tumor types, including colorectal, lung, ovarian and breast¹⁸⁻²¹. Surprisingly, in PDAC, ABC transporters, including ABCB1, have been associated with gemcitabine resistance^{13, 22-26} but not with paclitaxel resistance.

In the present study, we have generated three independent paclitaxel- and gemcitabine resistant PDAC models and found that ABCB1 is amplified in paclitaxel

Chapter 2

resistant, but not in gemcitabine resistant PDAC cells. We show that pharmaceutical or genetic inhibition of ABCB1 effectively restores paclitaxel sensitivity in the resistant cell lines. We show that ABCB1 is expressed heterogeneously in PDAC patients. Moreover, as clinical trials of currently available ABCB1 inhibitors have not proven successful due to lack of efficacy or toxicity^{21, 27}, we screened a kinase-inhibitor (KI) library for KIs that attenuate efflux of ABCB1 substrates, thereby overcoming paclitaxel resistance. We identified several novel KIs that can be further (pre) clinically explored as therapeutic strategies in combination with paclitaxel to overcome paclitaxel resistance in PDAC and other cancers.

Methods

Materials and cell culture

Three PDAC cell lines were used: Patu-T (mesenchymal phenotype), kindly provided by Dr. Irma van Die (Amsterdam UMC, Amsterdam, The Netherland), Suit-2.028 (epithelial phenotype) and Suit-2.007 (mesenchymal phenotype), kindly provided by Dr. Adam Frampton (Imperial College London, London, UK). Patu-T were maintained in DMEM, supplemented with 10% heat-inactivated bovine fetal serum and 1% penicillin/streptomycin, while both Suit-2 cell lines were cultured in RPMI supplemented as described above. All cells were kept in humidified atmosphere of 5% CO₂ and 95% air at 37 °C, subcultured twice a week, tested monthly for mycoplasma contamination by MycoAlert Mycoplasma Detection Kit (Westburg, Leusden, The Netherlands) and cell identity was verified by short tandem repeats (STR) profiling.

Gemcitabine was kindly provided by Eli Lilly Corporation (Indianapolis, IN, USA) and dissolved in sterile water. Paclitaxel and verapamil were obtained from Sigma (T7402 and V4629, Sigma-Aldrich, St. Luis, MO, USA).

Generation of resistant cell lines

To establish gemcitabine-resistant (GR) and paclitaxel-resistant (PR) cell lines, concentrations causing 50% reduction in cell growth (IC_{50}) were determined in parental cells. Cells were then exposed to the respective IC_{50} of the drug and grown for at least 2 weeks with the drug until reaching 80% confluence. After acquiring resistance, the drug concentration was doubled ($2 \times IC_{50}$), and cells were cultured until they could grow to confluence. The process was repeated with stepwise increasing drug concentrations until the maximum tolerated concentration was reached after 6–12 months. Parental cells never exposed to the drug were cultured in parallel with the resistant cells. To determine stable resistance, PR and GR cells were grown in drug-free medium and baseline growth and resistance to the maximum tolerated concentration was analyzed by SRB assay at regular intervals for up to 2 months. The resistance factor was calculated as the ratio of the IC_{50} of resistant versus IC_{50} of parental cells. For $IC_{50} > 12 \mu M$, the resistance factor was calculated using the maximum drug concentration used in the SRB assay. Batches of resistant cells used in experiments were maintained in drug-free medium ≤ 2 months.

Immunohistochemistry

Expression of ABCB1 in PDAC patients was evaluated by immunohistochemistry (IHC) in paraffin-embedded tumor specimens from 32 PDAC patients who underwent resection and were treated with gemcitabine ($1,000 \text{ mg/m}^2$) plus nab-paclitaxel (125 mg/m^2) as first-line therapy. All specimens were obtained after patient's written consent approved by the Ethics Committee of "Area Vasta Emilia Nord" (protocol code 12003—17/03/2021). Tissue sections were stained overnight with rabbit anti-human ABCB1 (E1Y7S, mAb #13978; Cell Signaling Technology; dilution 1:400). Sections were reviewed independently by two researchers blinded to clinical data, who scored the immunostaining on the basis of staining intensities and number of stained cells as "low" or "high". Overall survival (OS) was calculated from the date of pathologic diagnosis (i.e., the date of surgery/biopsy) to the date of death. OS curves were constructed using Kaplan–Meier method, and differences were analyzed using log-rank test with SPSS v.25 statistical software (IBM).

Chapter 2

SRB assay

For sulforhodamine B (SRB) assay, cells were seeded in 96-well flat bottom plates at a density of 3000–4000 cells/well. After 72 h of drug exposure, plates were fixed with 50% TCA and incubated with 0.4% SRB at room temperature avoiding light. Plates were washed with 1% acetic acid to remove unbound SRB and air dried. 10 mM Tris was used to extract protein-bound dye and optical density was measured with a BioTek Synergy HT plate reader (SN 269140, BioTek Instruments Inc.) at 490 and 540 nm. IC_{50} was determined through interpolation in Graphpad-Prism (version 9.0, Intuitive Software for Science, USA).

RT-qPCR and DNA-qPCR

For RT-qPCR, RNA was isolated with an RNEasy Plus Mini kit (QIAGEN, Cat. 74136). 800 ng RNA was used to generate cDNA with the Thermo Scientific RevertAid H Minus First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA). For DNA-qPCR, genomic DNA was isolated with the GenElute™Mammalian Genomic DNA Miniprep kit, following manufacturer instructions (Cat. GIN350, Sigma-Aldrich, St. Luis, MO, USA). RNase A solution (provided with the kit, 1:10 dilution) was used to obtain RNA-free DNA. 7.5 ng of genomic DNA was used as template. qPCR was performed in triplicate using the PowerUp™ SYBR™ Green Master Mix (Thermo Fisher Scientific, Waltham, MA, USA) in a QuantStudioTM 6 Flex Real-Time PCR system (Applied Biosystems®, ThermoFisher Scientific, Waltham, MA, USA). Primers were from Sigma-Aldrich (St. Louis, MO, USA) and were directed against exon-exon boundaries for RT-qPCR or directed against intron–exon boundaries or introns for DNA-qPCR (Supplemental Table S1). Relative mRNA expression and relative DNA amount was calculated using the $2^{-(\Delta\Delta Ct)}$ method with *ACTB* and *GAPDH* as reference genes.

Western blot

Cells were lysed with RIPA buffer supplemented with 1% protease/phosphatase inhibitor cocktail (PIC, Sigma-Aldrich, St. Luis, MO, USA), 40 µg lysates were separated by SDS–polyacrylamide gel electrophoresis and transferred to PVDF membranes. Membranes were incubated overnight at 4°C with rabbit-anti-human ABCB1 (E1Y7B; mAb #13,342; Cell signaling Technology; dilution 1:1000) and mouse-anti-human β-actin (sc-47778; Santa Cruz Biotechnology, Santa Cruz, CA, USA; dilution 1:1000) antibodies, followed by incubation with HRP-conjugated anti-rabbit (#7074;

Cell Signaling Technology; dilution 1:2000) and Alexa Fluor® 647-conjugated anti-mouse (115–605-146; Jackson ImmunoResearch, Bio-Connect, Huissen, The Netherlands; dilution 1:1000) secondary antibodies for 1 h at room temperature. Signals were detected using enhanced chemiluminescence (ECL) and fluorescence readouts.

Hoechst exclusion assay

Cells were seeded at a density of 7000 cells/well in 96-well flat bottom black imaging plates (#655090; Greiner Bio-One™). Cells were allowed to attach for 8 h and then treated with 1 μ M of the selected KI, 10 μ M verapamil, or DMSO as negative control. Each condition was tested in triplicate wells. 24 h after seeding, 1 μ g/mL Hoechst33342 was added followed by an additional 2-h incubation. Subsequently, all wells were aspirated and received fresh medium including the respective inhibitors, without Hoechst33342 and plates were placed in a Nikon Eclipse Ti confocal microscope equipped with an automated stage, temperature and CO₂-controlled incubator for live imaging and a Plan Apo \times 20/0.75 NA objective (Nikon Instruments Inc., Melville, NY, USA). Total intensity of nuclear Hoechst33342 was calculated with CellProfiler²⁸ after watershed segmentation in FIJI-ImageJ²⁹. The intensity values of three images from three replicate wells were averaged for each condition. Values of experimental groups were normalized to those of the DMSO control group.

siRNA mediated ABCB1 and Sorcin knockdown

Cells were reverse transfected with 50 nM SMARTpool siGENOME siRNAs (Dharmacon) using INTERFERin transfection reagent (Polyplus; 409–50). A mixture of siRNAs targeting all kinases in the human genome, diluted to a total concentration of 50 nM with a concentration for each individual siRNA \sim 0.05 nM was used as control (siKINASEpool). Medium was refreshed after 24 h. For SRB assays, 3000 cells/well were seeded in triplicate wells in 96-well flat bottom plates. For RT-qPCR, 120,000 cells/well were seeded in duplicate wells in 24-well plates. At 48 h and 72 h post-transfection, cells in 24-well plates were processed for RT-qPCR and cells in 96-well plates were incubated for an additional 72 h in presence of DMSO or paclitaxel and subsequently processed for SRB assay.

Extrachromosomal DNA analysis

Cells in the exponential growth phase (70% confluent) were treated with colcemid (KaryoMax, #15212012, Gibco™) for 1-2 h at a final concentration of 0.1 μ g/ml. Cells

Chapter 2

were then detached by trypsinization, collected, and treated with a hypotonic solution (75 mM KCl) for 15 min. Next, cells were fixed in Carnoy's fixative (3:1 Methanol:Glacial acetic acid), washed three times and resuspended in 200 μ L of Carnoy's solution. Finally, metaphase chromosomes were prepared by dropping the cell suspension onto glass slides and mounted with ProLongTM Diamond Antifade mountant containing DAPI (Invitrogen, P36966, Waltham, MA, USA). Chromosomes and extrachromosomal DNA (ecDNA) were visualized with a Nikon Eclipse Ti2 confocal microscope, with a 60X objective and a 2 \times digital magnification.

Kinase inhibitor screening

The L1200 library from Selleckchem[®] (Munich, Germany) was used, containing 760 KIs that were dissolved in DMSO or water at a concentration of 10 mM or 1 mM. 3000 cells/well were seeded in 96-well flat bottom plates. After 24 h cells were treated with DMSO only (0.1%), 1 μ M KI and DMSO, or 1 μ M KI in combination with 0.1 μ M paclitaxel. 10 μ M verapamil was used as a positive control. After 72 h, cells were fixed and analyzed using an SRB-assay. The KI library was screened in single technical replicates, and the experiment was repeated in two biological replicates. Rescreening of selected KIs with SRB assay was performed in duplicate technical replicates and the experiment was repeated in three biological replicates.

Bottom-up proteomics sample preparation

For bottom-up proteomics, peptides were prepared by lysis of cells with a 5% SDS solution and Roche cOmplete[™] Mini EDTA-free Protease Inhibitor Cock-tail (Merck Darmstadt, Germany), followed by sonication (10 min, every 30 s) (Bioruptor Pico Diagenode, Belgium). Next, protein lysates were quantified using a modified Pierce Micro BCA assay (Termo Fisher Scientific Rockford, IL), and 5 μ g of proteins were used for peptide digestion. Prior to digestion, proteins were reduced with 20 mM dithiothreitol (Merck Darmstadt, Germany) at 45 °C for 30 min, alkylated with 40 mM iodoacetamide (Merck Darmstadt, Germany) for 30 min at room temperature in the dark and acidified with 2.5% phosphoric acid. Finally, proteins were diluted with 90% methanol/100 mM triethylammonium bicarbonate (TEAB) (Merck Darmstadt, Germany) for efficient trapping in Micro S-Trap columns (ProtiFl, Farmingdale, NY, USA). Digestion was performed in the S-Trap overnight at 37 °C using Trypsin/Lys-C Mix Mass Spec Grade (Promega, Walldorf, Germany), followed by elution in 50 mM TEAB, 0.2% formic acid (FA) and 50% acetonitrile (ACN) (Merck Darmstadt, Germany). Eluted peptides were dry-evaporated and resuspended in 10% FA

solution for subsequent tandem mass spectrometry analysis (LC–MS/MS), as described in Supplementary Methods. The MS proteomics data have been deposited to the ProteomeX-change Consortium via PRIDE (accession number PXD040930).

RNA-seq

Total RNA was extracted from cells using the MiRVAna kit (Ambion, Thermo Fisher Scientific). Library preparation was performed using the Illumina TruSeq Stranded total RNA Library Prep gold Kit (20020598, Illumina Inc., San Diego, USA) and Agen-count AMPure XP beads (Beckman Coulter, Brea, USA). Library concentration was determined using a Qubit dsDNA BR kit (Thermo Scientific), and the size distribution was examined with an Agilent Bioanalyzer. Libraries were paired-end sequenced (2 × 75 bp) on a NextSeq500 (Illumina). BclTo-Fastq was used for the preprocessing of the raw data (trimming and filtering), then FASTQ files were checked for read quality and adapters were removed with Trimmomatic. The resulting reads were then mapped to the human reference genome (GRCh38) with STAR mapping tool (version 2.5.3a) and gene counts extracted with HTSeq. Raw RNA-sequencing data have been deposited on GEO database under accession number GSE228106.

Chapter 2

Differential expression analysis

Differential expression analysis was performed with R package *Deseq2* (version 1.22.2) for RNA-seq data and R package *Limma* (version 3.38.3) for proteomics data. In all datasets, black and white cases were allowed retaining the 0 for both parental and resistant cells. For RNA-seq data, only genes having a total sample count > 10 were retained. Volcano plots were generated using R package *EnhancedVolcano*, principal component analysis and sample correlation analyses were performed with *plotPCA* function of *DeSeq2* R package and *pheatmap* R package (version 1.0.12). Finally, the R-package *ggvenn* was used to count the genes significantly upregulated in common among the cell lines and between RNA-seq and proteomics datasets.

Statistical analysis

Experiments were performed at least 3 times and data are expressed as mean \pm SD of 3 experiments performed in triplicate, unless otherwise specified. To compare between two groups, a two-tailed unpaired Student's t-test was used. For multiple groups comparisons, an ordinary one-way ANOVA multiple comparison test with Dunnet's post-hoc test was used, unless otherwise specified in figure legends. Statistical significance was set at $p < 0.05$ and is indicated by *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$.

Results

Establishment of PDAC resistant cell lines

To study resistance to paclitaxel in PDAC, resistant cell lines were established by adaptation to a step-wise increase in the exposure dose over the course of 6–12 months (Fig. 1A). For this purpose, Patu-T, Suit- 2.007, and Suit-2.028 cell models were used, and gemcitabine was used as an alternative chemotherapy in parallel to paclitaxel. The IC_{50} values, as extrapolated from the dose–response curves for paclitaxel or gemcitabine, ranged from 2 to 16 nM for all parental cell lines (Fig. 1B and Supplemental Table S2). IC_{50} values for the resistant derivatives GR and PR were in the μ M range (1.6–3.0 μ M for PR; 0.7–12 μ M for GR), with resistance factors > 100 -fold that remained stable for at least 2 months of culturing in absence of the drug (Fig. 1B and Supplemental Table S2).

We did not observe cross-resistance: GR cells showed similar or even greater sensitivity to paclitaxel as compared to parental cells and PR cells showed similar or even greater sensitivity to gemcitabine as compared to parental cells (Fig. 1C and 34

Supplemental Table S2). All together these results indicated that resistant models were stable and did not show cross-resistance, therefore providing a valid model to investigate drug-specific chemoresistance mechanisms.

ABCB1 expression is induced in PR but not GR models

To investigate a common molecular mechanism for paclitaxel resistance in PR cells, Patu-T and Suit-2.028 parental (CTR) and PR cells were subjected to RNA-seq and proteomics analysis. Both RNA-seq and proteomics were performed in triplicate and correlation plot and principal component analyses showed a good separation among CTR and resistant cells (Fig. S1A, B). For differential expression of RNA and proteins, cutoff criteria were set at $\log_{2}FC < -2$ or > 2 and $p\text{-val} < 0.05$. RNA-seq analysis identified 720 upregulated genes in PR cells (284 unique for Patu-T; 403 unique for Suit-2.028; 34 in common) (Fig. 2A and Fig. S2).

Chapter 2




Figure 1. Establishment of paclitaxel and gemcitabine resistant PDAC models. **(A)** Graphical representation of the methodology used for generation of PR and GR models. **(B)** Growth curves of PR (upper panel) and GR (lower panel) cells, together with the parental cells, exposed to increasing concentrations of gemcitabine or paclitaxel. **(C)** Sensitivity of PR cells to gemcitabine and GR cells to paclitaxel. **(B-C)** Mean and SD of triplicates are shown. IC₅₀ values were calculated as mean of 3 independent experiments, each performed in triplicate.

ABCB1 overexpression as target to combat paclitaxel resistance

Proteomics analysis identified a total of 5309 (Patu-T) and 5231 (Suit-2.028) unique proteins and 209 proteins were upregulated in PR cells (60 unique for Patu-T; 142 unique for Suit-2.028; 7 in common). Intersection of RNA-seq and proteomics data identified ABCB1 and SRI as the only genes whose expression was upregulated both at the transcript and protein level in both PR models (Fig. 2B and Supplemental Table S3). Other ABC transporters were not upregulated in both cell lines and in both RNA-seq and proteomics data sets (Fig. S3). We validated upregulation of ABCB1 by RT-qPCR and Western Blot. ABCB1 was strongly upregulated at the mRNA and protein level in all PR cell lines, as compared to GR and parental cell lines (Fig. 2C, D; Fig. S4). Even though Suit-2.028 GR cells showed some increase in *ABCB1* mRNA expression, ABCB1 protein levels were not affected. These findings indicated that induction of ABCB1 is a common event in PR PDAC models but not in GR models.

ABCB1 represents a target for sensitization to paclitaxel in PDAC

The functional consequence of increased ABCB1 expression was determined using a Hoechst-efflux assay. Similarly to paclitaxel, the live nuclear stain Hoechst33342 is a substrate of multiple ABC-transporters, including ABCB1³⁰. Hoechst33342 readily stained nuclei in CTR and GR cells but was effectively excluded in PR cells after 2 h incubation (Fig. 2E). To confirm the clinical relevance of ABCB1, its expression and potential correlation with survival was evaluated in surgical specimens from PDAC patients who then received at least one cycle of gemcitabine + nab-paclitaxel as first-line therapy.

Chapter 2




Figure 2. ABCB1 overexpression in PDAC PR cell lines. **(A)** Venn diagrams showing the up-regulated mRNAs (upper panel) or proteins (lower panel) in Patu-T PR and Suit-2.028 PR

compared to the respective CTR. A list of the genes in common for each dataset can be found at Supplemental Table S3. **(B)** Venn diagram showing targets upregulated in both RNA-seq (Patu-T PR in green and Suit-2.028 in red) and proteomics analysis (Patu-T PR in blue and Suit-2.028 in yellow) in Patu-T PR and Suit-2.028 PR compared to the respective CTR. **(C)** Relative gene expression of *ABCB1* in CTR (blue), GR (green) and PR (red), measured by RT-qPCR. **(D)** Western blot analysis of *ABCB1* expression and β -actin (B-act) as loading control in the indicated CTR, GR, and PR cell models. Uncropped Western blot membranes can be found in Figure S4. **(E)** Representative confocal images of PDAC cell lines stained with 1 μ g/mL of Hoechst33342 for 2 h at 37 °C in growth medium. *Scale bar:* 100 μ m. **(F)** *ABCB1* expression levels assessed by immunohistochemistry (IHC) in surgical specimens from PDAC patients who were subsequently treated with gemcitabine/nab-paclitaxel as first-line therapy. Three specimens with low and three specimens with high expression levels are shown. *Scale bar:* 200 μ m

ABCB1 was expressed at different levels in these patients confirming its potential role as a personalized target for therapeutic intervention in PDAC patients (Fig. 2F). There was a trend towards a correlation with poor survival although in this small cohort this was not significant ($p = 0.0694$, Fig. S5A, B). To establish the role of *ABCB1* in PDAC paclitaxel-resistance, *ABCB1* activity was inhibited with the *ABCB1* inhibitor, verapamil³¹. Treatment with verapamil alone did not affect PR cell proliferation (Fig. S6A), but led to a marked increase in Hoechst nuclear staining in PR cells (Fig. 3A, B). In agreement, a dose-dependent increase in the sensitivity to paclitaxel was observed causing a~100–1000-fold decrease in the paclitaxel IC₅₀ when combined with 10 μ M verapamil (Fig. 3C, D). Moreover, verapamil did not affect gemcitabine sensitivity in Patu-T GR or CTR (Fig. S6B). As verapamil may have off-target effects in addition to *ABCB1* inhibition, the role of *ABCB1* in PDAC paclitaxel resistance was further confirmed using gene silencing. Indeed, siRNA-mediated *ABCB1* depletion strongly sensitized PR cells to paclitaxel as compared to controls (Fig. 3E). Together, these data confirmed the specific role of *ABCB1* induction in paclitaxel resistance as a common mechanism underlying paclitaxel-resistance in all three PDAC models.




Figure 3. ABCB1 inhibition restores PR cell lines paclitaxel sensitivity. **(A)** Representative confocal images of PDAC PR cell lines treated O/N with either 10 μ M verapamil or DMSO as a control and stained with 1 μ g/mL of Hoechst33342 for 2 h at 37 °C in growth medium. Scale bar: 100 μ m. **(B)** Quantification of Hoechst signal total intensity with CellProfiler upon DMSO (red) or 10 μ M verapamil (green) treatment. **(C)** Representative growth curves of the 3 PR resistant cell models exposed for 72 h to paclitaxel concentration ranges, combined with

0.1% DMSO (red triangles), 5 μ M verapamil (black diamonds) or 10 μ M verapamil (green squares). Mean and SD of triplicates is shown. **(D)** Concentrations of paclitaxel causing 50% reduction in cell growth determined in absence or presence of 5 μ M or 10 μ M verapamil. Mean \pm SEM for 3 independent experiments is displayed. As 50% growth inhibition was not fully reached in PR cells exposed to only paclitaxel, values from Supplemental Table S2 are displayed. **(E)** Relative proliferation (compared to siKINASEpool control) of Patu-T PR cells 72 h post-treatment with the indicated siRNA SMARTpools (50 nM) and paclitaxel concentrations, analyzed by SRB assay. Verapamil is used as positive control for ABCB1 inhibition

ABCB1 gene locus is amplified and gene expression is upregulated in PR cells

ABCB1 overexpression can be caused by amplification of the gene locus 7q21.12 in neuroblastoma, lung, and ovarian cancers³². To elucidate the mechanism of upregulation in the three PR PDAC models, mRNA expression of the *ABCB4*, *ADAM22*, *TP53TG1*, and *SRI* genes that reside in the *ABCB1* locus (Fig. 4A), was measured by RT-qPCR. Expression of each of these genes was increased in PR cells as compared to the parental cells for each of the three PDAC models (Fig. 4B-D), suggesting amplification or de-repression of the gene locus. We explored locus amplification by DNA-qPCR in the Patu-T model. Increased signals for all four genes were detected in PR but not in GR cells as compared to CTR cells, confirming locus amplification (Fig. 4E).

We next investigated the presence of ecDNA that has been associated with increased copies of oncogenes and chemo-resistance in many types of cancer^{33, 34}. Similar to parental or GR cells, no ecDNA was present in PR cell metaphase spreads (Fig. 4F). This demonstrated that ABCB1 overexpression in PR PDAC cells was caused by ABCB1 locus amplification which does not involve ecDNA.

Sorcin depletion does not affect proliferation of PR cells treated with paclitaxel

SRI, which was the only gene up-regulated at the mRNA and protein level in all three PR PDAC models alongside *ABCB1* (Figs. 2B, 4B-D), encodes the calcium-binding protein Sorcin that is associated with cancer progression³⁵ and can activate expression of ABCB1³⁶. We therefore asked if depletion of SRI could reduce ABCB1 levels and restore paclitaxel sensitivity in PR PDAC cells.




Figure 4. Expression of genes in *ABCB1* locus is upregulated in PR cells. **(A)** Graphic visualization of *ABCB1* amplicon on the locus 7q21.12. **(B-D)** Gene expression of *ABCB4*, *ADAM22*, *TP53TG1* and *SRI* measured by RT-qPCR in PR (red) relative to CTR cells (blue) for the 3 indicated cell models. Brown-Forsythe and Welch ANOVA with Dunnett's T3 post hoc test was used. **(E)** Relative DNA amount of *GAPDH*, *ABCB1*, *ABCB4*, *ADAM22*, *TP53TG1* and *SRI* in

Patu-T CTR (blue), GR (green) and PR (red) cells, measured by DNA-qPCR and calculated as fold change ($2^{-\Delta\Delta Ct}$ compared to the parental). **(F)** Representative images of Patu-T CTR, GR and PR cell metaphases stained with DAPI. Note absence of ecDNA. *Scale bar: 20 μm.* **(G-H)** Gene expression of *SRI* **(G)** and *ABCB1* **(H)** in Patu-T PR cells transfected with the indicated siRNA SMARTpools (50 nM) measured by RT-qPCR relative to siKINASEpool samples. **(I)** Cell growth of Patu-T PR cells 72 h post-treatment with the indicated siRNA SMARTpools and paclitaxel concentrations, relative to siKINASEpool control samples. Verapamil (Vera) is used as positive control for ABCB1 inhibition.

However, siRNA-mediated silencing of *SRI* did not lead to reduced *ABCB1* expression (Fig. 4G, H) and, in agreement, did not affect paclitaxel resistance of Patu-T PR cells (Fig. 4I). This indicates that a previously described mechanism of ABCB1 regulation by *SRI* did not underlie ABCB1-mediated paclitaxel resistance in PDAC cells.

Compound screen identifies KIs targeting ABCB1-mediated paclitaxel resistance

Clinical trials with ABCB1 inhibitors on cancer patients have not been successful due to low efficacy or adverse effects^{21, 27}. As sorcin targeting proved unsuccessful, we took an unbiased approach to identify alternative pharmacological combinations to restore paclitaxel sensitivity in PR PDAC cells. We screened a library of 760 KIs in Patu-T PR cells. The KI library was screened at a fixed dose of 1 μM in combination with DMSO or paclitaxel at a fixed dose of 0.1 μM. A subset of KIs reduced proliferation of Patu-T PR cells below 50% exclusively when co-administered with paclitaxel (Fig. 5A, Supplemental Table S4). This subset did not show an enrichment for interaction with specific signaling pathways but several of these KIs had been previously shown to interact with ABCB1. In particular, tyrosine kinase inhibitors, including apatinib and SGI-1776 free base, have been described as ABCB1 inhibitors^{21, 37-39}. We further continued with apatinib and SGI-1776 free base as positive controls and a series of potent KIs detected in the screen for which an interaction with ABCB1 had not been previously shown (Supplemental Table S4). Sensitization to paclitaxel for PR PDAC cells was validated for each of these selected KIs in the Patu-T, Suit-2.028 and Suit-2.007 models (Fig. 5B and Fig. S7A). In agreement with ABCB1 inhibition by these KIs, each effectively suppressed Hoechst exclusion in the PR cells to a similar extent as that achieved by verapamil (Fig. 5C, D and Fig. S7B). To discriminate between inhibition of ABCB1 efflux function versus inhibition of expression of ABCB1, we measured ABCB1 mRNA expression in the PR models after 48 h of treatment with 1 μM of selected KIs. The effect of the KIs varied among cell lines and among KIs, but none of them reduced ABCB1 expression to a level comparable to that in CTR cells (Fig. S8). Moreover, changes in expression induced by KIs did not match

Chapter 2

their effect on Hoechst exclusion or cell proliferation in the presence of paclitaxel, indicating that these KIs primarily act as inhibitors of ABCB1 function. Altogether, these findings identify novel KIs that may be used to target ABCB1-mediated paclitaxel resistance.

Discussion

Chemoresistance is a major hurdle in the treatment of PDAC patients and understanding how to revert resistance to available treatments is of crucial importance. Gemcitabine resistance has been extensively investigated in PDAC, while little research has been performed on paclitaxel resistance^{12, 13}. We find that ABCB1 over-expression is a shared response to continued exposure to paclitaxel in three independent PDAC models and is not associated with gemcitabine resistance in those models. ABCB1 is involved in multidrug resistance of many solid cancers^{27, 40-42}. Taxols, in particular paclitaxel, are among the substrates of this transporter. However, the role of ABCB1 in resistance to paclitaxel has not been addressed in pancreatic cancer.

Interestingly, previous studies using pancreatic and other cancer cell lines have shown that ABCB1 is involved in gemcitabine resistance^{13, 22-26}. Our data do not support such a role: gemcitabine exposure did not induce ABCB1 expression (besides some increase at the mRNA level in some instances which was not mirrored by enhanced protein levels). Moreover, the induction of ABCB1 in paclitaxel resistant PDAC cells did not lead to cross-resistance to gemcitabine and inhibition of ABCB1 through verapamil did not alter GR cells sensitivity to gemcitabine. The aforementioned studies largely focused on HNF1A or PLK1 mediated gemcitabine resistance mechanisms that involved ABCB1^{22, 23, 25} while Chen et al. did observe increased ABCB1 expression in SW1990 cells treated with gemcitabine²⁴.

ABCB1 overexpression as target to combat paclitaxel resistance




Figure 5. KI library screen to identify synthetic lethality with paclitaxel in PR PDAC cells. **(A)** Scatter plot showing relative proliferation of Patu-T PR cells treated with 760 KIs (1 μ M) in absence or presence of 0.1 μ M paclitaxel, as assessed by SRB. Dots represent the mean of two independent experiments. Labeled dots indicate 0.1% DMSO control (dark grey), 0.1 μ M paclitaxel only (purple), 0.1 μ M gemcitabine (green), and 10 μ M verapamil (orange). Red

Chapter 2

box, enlarged on the right, indicates compounds synergizing with paclitaxel, and blue dots indicate compounds already known to interact with ABCB1. **(B)** Confirmation of screen hits. KIs were tested at 1 μ M concentration in combination with DMSO (black) or 0.1 μ M paclitaxel (red) and proliferation was assessed after 72 h of treatment. Dotted line represents DMSO control (100%). KIs were tested in technical duplicates and controls in triplicates. Mean and SD from 3 independent experiments is displayed (dots indicate individual data points). Ordinary one-way ANOVA was performed, followed by Šídák's multiple comparisons test. **(C)** Representative confocal images of PDAC PR cell lines treated O/N with either 1 μ M KIs, 10 μ M verapamil or DMSO as a control and stained with 1 μ g/mL of Hoechst33342 for 2 h at 37 °C in growth medium. *Scale bar: 100 μ m.* **(D)** Quantification of Hoechst signal total intensity with CellProfiler upon the different treatments. Dotted line represents Relative total intensity = 1.

Notably, a different study in fact reported increased sensitivity to gemcitabine in a panel of cancer cell lines overexpressing ABCB1⁴³, and we find a similar trend in some of our models. Taken together, there is no direct evidence involving ABCB1 in gemcitabine resistance and our study indeed argues against such a mechanism in PDAC cells.

Previous studies showed that ABCB1 overexpression can be caused by gene locus amplification ⁴⁴. Indeed, the expression of 4 genes belonging to locus 7q21.12 (*ABCB4*, *ADAM22*, *TP53TG1* and *SRI*) is also increased in PR cells. We discriminate between de-repression and amplification by DNA-qPCR, further confirming locus amplification as the underlying mechanism. Gene amplification and chemo-resistance have been linked to the presence of ecDNA³³. The continuous exposure to a drug like paclitaxel affecting the cell cycle could lead to genomic instability and therefore to the generation of ecDNA fragments⁴⁵ but we did not find evidence for this. The fact that DNA-qPCR fold-change values were similar for the tested genes in the 7q21.12 locus, while RT-qPCR fold-change values for the same genes differed considerably, suggests that additional mechanisms, on top of locus amplification, may regulate paclitaxel-induced ABCB1 overexpression.

One such mechanism we considered involves *SRI*/Sorcin. *SRI* is located on the same gene locus as *ABCB1* and is often co-amplified in multidrug-resistant cancers^{32, 35}. In our experiments, *SRI* was the only candidate specifically induced by paclitaxel along with *ABCB1* in the transcriptomics and proteomics datasets for Patu-T PR and Suit-2.028 PR. *SRI* encodes Sorcin, a calcium-binding protein that has been associated with increased tumor aggressiveness^{35, 46} and can induce *ABCB1* expression in

leukemia³⁶. In particular, Sorcin activates Protein Kinase A (PKA)-CREB1 signaling leading to activation of the ABCB1 promoter at cAMP-Response elements (CRE). Our results argue against this mechanism in PDAC paclitaxel resistance: SRI knockdown did not affect ABCB1 expression and failed to sensitize Patu-T PR cells to paclitaxel. It is possible that ABCB1 regulation is different in PDAC cells as compared to leukemic cells or the gradual increase in ABCB1 and SRI caused by paclitaxel differs from engineered SRI overexpression, as used by Yamagishi and colleagues³⁶. Moreover, the impact of sorcin on ABCB1 transcription is modulated by the presence of other mechanisms regulating calcium ion homeostasis, which may vary between cell types⁴⁷.

Our findings in a small patient cohort show that ABCB1 is expressed in PDAC patients that after resection received at least one cycle of gemcitabine + nab-paclitaxel treatment. We observe a trend towards a correlation of ABCB1 expression with poor survival, although in this small cohort it was not statistically significant. It will be interesting to assess a larger cohort and compare to patients that have received a different therapy regimen such as FOLFIRINOX. Nevertheless, this indicates ABCB1 is expressed and may represent a target for chemosensitization to paclitaxel in PDAC patients. We confirmed its role as a candidate target for attenuating paclitaxel resistance in PDAC using gene silencing and the ABCB1 inhibitor, verapamil. Unfortunately, verapamil or other ABCB1 inhibitors have not performed well in the clinic. Reasons for the failure of ABCB1 inhibitors in clinical trials include lack of efficacy or dose-limiting toxicity^{21, 27}.

Our KI screen identified novel candidate strategies to sensitize PDAC cells to paclitaxel without affecting growth in the absence of the chemotherapy. We found two compounds (i.e., apatinib and SGI-1776 free base) that have already been reported as ABCB1 inhibitors^{38, 39}. Interestingly, several compounds that were identified as ABCB1 inhibitors in different cancers failed to sensitize PDAC cells in our screen (i.e., erlotinib⁴⁸, imatinib⁴⁹, and nilotinib⁵⁰). Whether this reflects different inhibitory mechanisms or differences in potency is currently unknown, but it underscores the need to test each drug in the appropriate cancer type. We also identified KIs such as nazartinib, naquotinib, and derazantinib, that have not been previously implicated in PDAC paclitaxel resistance or ABCB1 inhibition. Using a Hoechst efflux assay, we confirmed these KIs act by inhibiting ABCB1. For some KIs and in some PR models, inhibition of ABCB1 expression was observed. However, this never reduced

Chapter 2

it to the nearly absent levels observed in CTR cells. Moreover, this effect did not correlate with the efficacy of the KIs in attenuating Hoechst efflux or cell proliferation in the presence of paclitaxel. This indicates that these KIs mainly act by suppressing ABCB1 efflux activity and it points to candidate strategies for combination therapies for chemosensitization. Interestingly, nazartinib, naquatinib, and derazantinib have already passed phase I clinical trials [NCT02108964⁵¹, NCT02500927⁵², NCT03230318⁵³], suggesting that their safety profile is acceptable. Apatinib mono treatment showed *in vivo* tumor growth arrest in PDAC xenograft models⁵⁴ and synergized with paclitaxel in gastric cancer murine models^{55, 56}. Apatinib also reverted breast cancer multidrug resistance *in vivo*³⁸ and it is being tested in phase I and II clinical trials in combination with different chemotherapeutic agents, including paclitaxel [NCT02697838⁵⁷]. Results from these trials will provide more information on the clinical relevance and feasibility of combining KIs with ABCB1 substrates to improve patient response to therapy.

Acknowledgements

Part of Figure 1A was drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (<https://creativecommons.org/licenses/by/3.0/>). Imaging data were stored and organized with OMERO Database⁵⁸.

Authors' contributions

C.B. designed, executed and analyzed the experiments, prepared figures, and wrote the manuscript; A.G. designed, executed and analyzed the experiments, prepared figures and wrote the manuscript; T.M.S.H., B.C. executed experiments; V.vdN., B.vdW., A.Z., B.C., I.G. designed experiments; M.C., G.M., A.B., F.F. executed experiments and analyzed -omic results; T.S., L.A.M.D. supervised the study; E.G. designed experiments and supervised the study; E.H.J.D. designed experiments, supervised

the study and wrote the manuscript. All authors read and approved the final version of the manuscript.

Funding

E.G, E.H.J.D, T. S, A.G. and C.B. were supported by the Dutch Cancer Society (KWF Research Grant # 11957). E.H.J.D. was supported by Dutch Research Council (NWO; Science-XL grant 2019.022). G.M., and E.G. were supported by Italian Association of Cancer Research (AIRC, IG-grant) and by the Cancer Center Amsterdam Foundation (Proof-of-concept grant). L.A.M.D. and A.B. acknowledge support of the Fondazione Pisana per la Scienza ONLUS, under the project entitled “Precision Exosome Analysis for Early Diagnosis of Pancreatic Adenocarcinoma”. I.G. and E.G. were supported by the European organization for Research and Treatment of Cancer (EORTC GI Group’s Young Investigators grant).

Availability of data and materials

The dataset generated by RNA-seq data for this study is available at Gene Expression Omnibus (GEO) database with accession number GSE228106 and are available at the following URL: <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE228106>. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via PRIDE repository with the dataset identifier PXD040930 and 10.6019/PXD040930. All experimental datasets and documents generated in this study are available upon reasonable request to the corresponding author.

Declarations

Ethics approval and consent to participate

All specimens were obtained after patient’s written consent approved by the Ethics Committee of “Area Vasta Emilia Nord” (protocol code 12003—17/03/2021).

Consent for publication

Not applicable.

Competing interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021;71(3):209–49.
2. Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, et al. Cancer treatment and survivorship statistics, 2022. *CA Cancer J Clin.* 2022;72(5):409–36.
3. Sarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG, Kara- mouzis MV. Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy. *World J Gastrointest Oncol.* 2020;12(2):173–81.
4. Puik JR, Swijnenburg RJ, Kazemier G, Giovannetti E. Novel strate- gies to address critical challenges in pancreatic cancer. *Cancers.* 2022;14(17):4115.
5. Milella M, Bassi C, Boggi U, Brunetti O, Cavaliere A, Crippa S, et al. Evolving pancreatic cancer treatment: from diagnosis to healthcare management. *Crit Rev Oncol Hematol.* 2022;169:103571.
6. Robatel S, Schenk M. Current limitations and novel perspectives in pancreatic cancer treatment. *Cancers.* 2022;14(4):985.
7. Turpin A, Neuzillet C, Colle E, Dusetti N, Nicolle R, Cros J, et al. Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies. *Ther Adv Med Oncol.* 2022;14:175883592211180.
8. Ayasun R, Saridogan T, Gaber O, Sahin IH. Systemic therapy for patients with pancreatic cancer: current approaches and opportunities for novel avenues toward precision medicine. *Clin Colorectal Cancer.* 2022;22(1):2–11.
9. Chakrabarti S, Kamgar M, Mahipal A. Systemic therapy of metastatic pancreatic adenocarcinoma: current status, challenges, and opportunities. *Cancers.* 2022;14(11):2588.
10. Grasso C, Jansen G, Giovannetti E. Drug resistance in pancreatic cancer: impact of altered energy metabolism. *Crit Rev Oncol Hematol.* 2017;114:139–52.
11. Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, et al. nab- Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. *Cancer Discov.* 2012;2(3):260–9.
12. Comandatore A, Immordino B, Balsano R, Capula M, Garajovà I, Ciccolini J, et al. Potential role of exosomes in the chemoresistance to gemcitabine and nab- paclitaxel in pancreatic cancer. *Diagnostics.* 2022;12(2):286.
13. Marin J, Monte M, Macias R, Romero M, Herraez E, Asensio M, et al. Expression of chemoresistance-associated ABC proteins in hepatobiliary, pancreatic and gastrointestinal cancers. *Cancers.* 2022;14(14):3524.
14. Braun LM, Lagies S, Guenzle J, Fichtner-Feigl S, Wittel UA, Kammerer B. Metabolic adaptation during nab-paclitaxel resistance in pancreatic cancer cell lines. *Cells.* 2020;9(5):1251.

15. Parasido E, Avetian GS, Naeem A, Graham G, Pishvaian M, Glasgow E, et al. The sustained induction of c-MYC drives nab-paclitaxel resistance in primary pancreatic ductal carcinoma cells. *Mol Cancer Res.* 2019;17(9):1815–27.
16. Voisin T, Nicole P, Gratio V, Chassac A, Mansour D, Rebours V, et al. The orexin-A/OX1R system induces cell death in pancreatic cancer cells resistant to gemcitabine and nab-paclitaxel treatment. *Front Oncol.* 2022;12:904327.
17. Vasiliou V, Vasiliou K, Nebert DW. Human ATP-binding cassette (ABC) transporter family. *Hum Genomics.* 2008;3(3):281.
18. Chang YC, Kondapuram SK, Yang TH, Syed SB, Cheng SM, Lin TY, et al. The SMAC mimetic LCL161 is a direct ABCB1/MDR1-ATPase activity modulator and BIRC5/Survivin expression down-regulator in cancer cells. *Toxicol Appl Pharmacol.* 2020;401:115080.
19. Yamamoto M, Suzuki S, Togashi K, Sanomachi T, Seino S, Kitanaka C, et al. AS602801 sensitizes ovarian cancer stem cells to paclitaxel by downregulating MDR1. *Anticancer Res.* 2019;39(2):609–17.
20. Gupta P, Zhang YK, Zhang XY, Wang YJ, Lu KW, Hall T, et al. Voruciclib, a potent CDK4/6 inhibitor, antagonizes ABCB1 and ABCG2-mediated multi-drug resistance in cancer cells. *Cell Physiol Biochem.* 2018;45(4):1515–28.
21. Jaramillo AC, Saig FA, Cloos J, Jansen G, Peters GJ. How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance? *Cancer Drug Resist.* 2018;1(1):6–29.
22. Lu Y, Xu D, Peng J, Luo Z, Chen C, Chen Y, et al. HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1. *EBio-Medicine.* 2019;15(44):403–18.
23. Cao J, Yang J, Ramachandran V, Arumugam T, Deng D, Li Z, et al. TM4SF1 promotes gemcitabine resistance of pancreatic cancer in vitro and in vivo. *PLoS One.* 2015;10(12):e0144969.
24. Chen M, Xue X, Wang F, An Y, Tang D, Xu Y, et al. Expression and promoter methylation analysis of ATP-binding cassette genes in pancreatic cancer. *Oncol Rep.* 2012;27(1):265–9.
25. Song B, Liu XS, Rice SJ, Kuang S, Elzey BD, Konieczny SF, et al. Plk1 phosphorylation of Orc2 and Hbo1 contributes to gemcitabine resistance in pancreatic cancer. *Mol Cancer Ther.* 2013;12(1):58–68.
26. Yao M, Hong Y, Liu Y, Chen W, Wang W. N1-guanyl-1, 7-diaminoheptane enhances the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine via the inhibition of eukaryotic translation initiation factor 5A2. *Exp Ther Med.* 2017;14(3):2101–7.
27. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. *Nat Rev Drug Discov.* 2006;5(3):219–34.

Chapter 2

28. Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, et al. Cell Profiler: image analysis software for identifying and quantifying cell phenotypes. *Genome Biol.* 2006;7(10):R100.
29. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. *Nat Methods.* 2012;9(7):676–82.
30. Shapiro AB, Ling V. Positively Cooperative Sites for Drug Transport by P-Glycoprotein with Distinct Drug Specificities. *Eur J Biochem.* 1997;250(1):130–7.
31. Bellamy WT. P-glycoproteins and multidrug resistance. *Annu Rev Pharmacol Toxicol.* 1996;36:161–83.
32. Genovese I, Ilari A, Assaraf YG, Fazi F, Colotti G. Not only P-glycoprotein: amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. *Drug Resist Updat.* 2017;32:23–46.
33. Kim H, Nguyen NP, Turner K, Wu S, Gujar AD, Luebeck J, et al. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. *Nat Genet.* 2020;52(9):891–7.
34. Turner KM, Deshpande V, Beyter D, Koga T, Rusert J, Lee C, et al. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. *Nature.* 2017;543(7643):122–5.
35. Battista T, Fiorillo A, Chiarini V, Genovese I, Ilari A, Colotti G. Roles of Sorcin in drug resistance in cancer: one protein, many mechanisms, for a novel potential anticancer drug target. *Cancers (Basel).* 2020;12(4):E887.
36. Yamagishi N, Nakao R, Kondo R, Nishitsuji M, Saito Y, Kuga T, et al. Increased expression of sorcin is associated with multidrug resistance in leukemia cells via up-regulation of MDR1 expression through cAMP response element-binding protein. *Biochem Biophys Res Commun.* 2014;448(4):430–6.
37. Wu S, Fu L. Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells. *Mol Cancer.* 2018;17(1):25.
38. Mi YJ, Liang YJ, Huang HB, Zhao HY, Wu CP, Wang F, et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. *Cancer Res.* 2010;70(20):7981–91.
39. Mumenthaler SM, Ng PYB, Hodge A, Bearss D, Berk G, Kanekal S, et al. Pharmacological inhibition of Pim kinases alters prostate cancer cell growth and re-sensitizes chemoresistant cells to taxanes. *Mol Cancer Ther.* 2009;8(10):2882–93.
40. Vaidyanathan A, Sawers L, Gannon AL, Chakravarty P, Scott AL, Bray SE, et al. ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. *Br J Cancer.* 2016;115(4):431–41.

41. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. *Nat Rev Cancer*. 2002;2(1):48–58.
42. Sharma P, Singh N, Sharma S. ATP binding cassette transporters and cancer: revisiting their controversial role. *Pharmacogenomics*. 2021;22(18):1211–35.
43. Bergman AM, Pinedo HM, Talianidis I, Veerman G, Loves WJP, van der Wilt CL, et al. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. *Br J Cancer*. 2003;88(12):1963–70.
44. Calcagno AM, Ambudkar SV. The molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells. *Methods Mol Biol*. 2010;596:77–93.
45. Yan Y, Guo G, Huang J, Gao M, Zhu Q, Zeng S, et al. Current understanding of extrachromosomal circular DNA in cancer pathogenesis and therapeutic resistance. *J Hematol Oncol*. 2020;13(1):124.
46. Tong W, Sun D, Wang Q, Suo J. Sorcin enhances metastasis and promotes epithelial-to-mesenchymal transition of colorectal cancer. *Cell Biochem Biophys*. 2015;72(2):453–9.
47. Wang C, Xu X, Zhang P, Xiong S, Yuan J, Gao X, et al. Lipid-coated albumin-paclitaxel nanoparticles loaded with sorcin-siRNA reverse cancer chemo-resistance via restoring intracellular calcium ion homeostasis. *J Nanobiotechnol*. 2022;20(1):319.
48. Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. *Cancer Res*. 2007;67(22):11012–20.
49. Sims JT, Ganguly SS, Bennett H, Friend JW, Tepe J, Plattner R. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1. *PLoS One*. 2013;8(1):e55509.
50. Tiwari AK, Sodani K, Dai CL, Abuznait AH, Singh S, Xiao ZJ, et al. Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. *Cancer Lett*. 2013;328(2):307–17.
51. Tan DSW, Leighl NB, Riely GJ, Yang JCH, Sequist LV, Wolf J, et al. Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. *Lancet Respir Med*. 2020;8(6):561–72.
52. Azuma K, Nishio M, Hayashi H, Kiura K, Satouchi M, Sugawara S, et al. ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer. *Cancer Sci*. 2018;109(8):2532–8.

Chapter 2

53. Mazzaferro V, El-Rayes BF, Droz Dit Bussel M, Cotsoglou C, Harris WP, Damjanov N, et al. Derezantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. *Br J Cancer*. 2019;120(2):165–71.
54. Hu Y, Jing J, Shi Y, Zhang P, Dong D, Wu Y, et al. Apatinib inhibits pancreatic cancer growth, migration and invasion through the PI3K/AKT and ERK1/2/MAPK pathways. *Transl Cancer Res*. 2021;10(7):3306–16.
55. Xu Z, Hu C, Chen S, Zhang C, Yu J, Wang X, et al. Apatinib enhances chemosensitivity of gastric cancer to paclitaxel and 5-fluorouracil. *Cancer Manag Res*. 2019;29(11):4905–15.
56. Feng J, Qin S. The synergistic effects of Apatinib combined with cytotoxic chemotherapeutic agents on gastric cancer cells and in a fluorescence imaging gastric cancer xenograft model. *Onco Targets Ther*. 2018;24(11):3047–57.
57. Zhao S, Fan N, Li H, Liu J, Huang F, Chen Y, et al. Apatinib combined with paclitaxel-based chemotherapy in patients with taxane-resistant advanced gastric cancer: a single-arm exploratory study. *Ann Transl Med*. 2020;8(19):1233.
58. Allan C, Burel JM, Moore J, Blackburn C, Linkert M, Loynton S, et al. OME Remote Objects (OMERO): a flexible, model-driven data management system for experimental biology. *Nat Methods*. 2012;9(3):245–53.

Supplementary Materials

The online version contains supplementary material available at <https://doi.org/10.1186/s13046-023-02879-8>. **Additional file 1: Supplementary methods.** LC-MS/MS analysis and label-free quantification. **Additional file 2: Supplemental Table S1.** Primer sequences used for RT-qPCR and DNA-qPCR. **Additional file 3: Supplemental Table S2.** IC₅₀ values of the established resistant cell lines and CTR and the respective Resistance factors. **Additional file 4: Supplemental Table S3.** List of up-regulated RNAs and proteins shared between Patu-T PR and Suit-2.028 PR cells. Common hits in RNA-seq and proteomics data are indicated in bold. **Additional file 5: Supplemental Table S4.** Selected hits from KI-screen. **Additional file 6: Supplementary Fig. S1.** Correlation plots and Principal component analysis (PCA) of RNA-seq and proteomics data. **Additional file 7: Supplementary Fig. S2.** Volcano plots of differentially expressed genes/proteins for PR vs CTR cells. **Additional file 8: Supplementary Fig. S3.** Upregulation of ABC transporters in PR cells. Venn diagram showing upregulated ABC transporters in PR models. **Additional file 9: Supplementary Fig. S4.** Uncropped Western blot membranes for Patu-T, Suit-2.028 and Suit-2.007 CTR, PR, and GR cells stained for ABCB1 and B-actin. **Additional file 10: Supplementary Fig. S5.** ABCB1 upregulation correlates with poor survival. **Additional file 11: Supplementary Fig. S6.** Verapamil mono treatment does not affect PR cell proliferation and verapamil does not sensitize to gemcitabine. **Additional file 12: Supplementary Fig. S7.** KI screen validation in Suit-2.007 and Suit-2.028 PR cells. **Additional file 13: Supplementary Fig. S8.** KI treatment of PR cells does not decrease ABCB1 expression to level of CTR cells.

SUPPLEMENTARY METHODS

LC-MS/MS analysis and label-free quantification

Peptide samples were analyzed by nanoLC-MS/MS using an EASY-nLC 1000 interfaced with an Orbitrap Fusion Tribrid mass spectrometer equipped with an EASY spray source (Thermo Fisher Scientific, Waltham, MA, USA). Peptides were loaded onto a PepMap C18 precolumn (2 cm x 75 μ m internal diameter (ID), 3 μ m particle size, 100 \AA pore size) (Thermo Fisher Scientific, Waltham, MA, USA) and separated on a PepMap C18 column (50 cm x 75 μ m ID, 2 μ m particle size, 100 \AA pore size) (Thermo Fisher Scientific, Waltham, MA, USA) heated at 35 $^{\circ}\text{C}$ and with a constant flow rate of 300 nl/min. Peptide separation was carried out using a segmented gradient of 0.1% FA (mobile phase A) and ACN/0.1% FA (mobile phase B) as follows: from 5% to 22% mobile phase B in 104 min, from 22% to 32% in 15 min and from 32% to 90% in 10 min. MS data were acquired in positive ion mode using a spray voltage of 2.0 kV, sheet gas set to 1 to minimize neutral contamination and an ion transfer tube temperature of 275 $^{\circ}\text{C}$. The MS1 survey scan was acquired using the orbitrap (OT) analyzer within a mass range of 375 – 1200 m/z, resolving power of 120.000 FWHM (at 200 m/z), RF lens value of 60%, maximum injection time of 50 ms and maximum ion count of 400000. MS2 was performed using the TopSpeed method in which the most intense precursor ions (2 – 7 charge states and a minimum intensity threshold of 5000) were isolated with an isolation window of 1.6 m/z and fragmented by higher energy collisional dissociation (HCD) at a normalized collision energy (NCE) of 27%. The total cycle time was 3 s. Fragment ion detection was performed in the dual-pressure ion trap (IT) with the maximum number ions set to 2000 and a maximum injection time of 300 ms. A dynamic exclusion of 60 s was enabled to avoid the selection of the same precursor ion during its chromatographic elution. Raw files were uploaded into Proteome Discoverer software (v2.1) (Thermo Fisher Scientific, Waltham, MA, USA) and queried against the human UniprotKB/Swiss-Prot TrEMBL database (202160 sequences, September 2021) using the SEQUEST database search algorithm. Peptide identification was performed using a mass tolerance of 10 ppm and 0.6 Da for precursor and fragment ions respectively, trypsin/Lys-C as endoproteases and up to two missed cleavages. Cysteine carbamidomethylation was set as a static modification (+57.021464 Da) while methionine oxidation (+15.994915 Da) and protein N-Terminal acetylation (+42.010565

Da) were both set as variable modifications. Peptide spectrum matches (PSMs) were determined using a 1% false discovery rate (FDR), using the Percolator module. Protein abundances were exported from Proteome Discoverer and normalized over the sum within each cell line dataset. The equality of variances was assessed, and selected proteins were tested for significance using a Student's two-tailed t-test. The MS proteomics data have been deposited to the ProteomeXchange Consortium via PRIDE (accession number PXD040930).

Chapter 2

RT-qPCR	Forward	Reverse
ABCB1	GGCTACATGAGAGCGGAGGAC	TTCCGTTGCACCTCTGGTC
ABCB4	GAAAGGCCAGACACTAGCCC	ACCATCGAGAAGCACTGTCC
TP53TG1	GAGCTGTCTTAACCTGCGG	GAGGGTTGGGTACCTTCGTG
ADAM22	CCGCGAAGCACAATGCAG	CAACATGAGTCAACTGCGGG
SRI	TCCGCTGTATGGTTACCTTGC	GTGCCAGACATATCTCTATCCAG
ACTB	ATTGCCGACAGGATGCAGAA	GCTGATCCACATCTGCTGGAA
GAPDH	TCGGAGTCAACGGATTTGGT	TTCCCGTTCTCAGCCTTGAC
DNA qPCR	Forward	Reverse
ABCB1	CAAGGCAATTCACAGACACAGG	CACTTCAGTTACCCATCTGAA
ABCB4	AGCCAAGGGTTAGGTACTG	CTAAAGGCTGAGACCAGCCAG
TP53TG1	CTCAGATTTGGTGGCAACTTTCA	GGAAGCAGCCAACAGCAAATT
ADAM22	TGAGGGAACCAAAAGCTCCC	CATGGCCCCTTACCCCTACT
SRI	TGTTGGGCTCACATGAAGGT	GGATGGGGTGCCATTCA
ACTB	CACTCCAAGGCCGCTTACA	CACTCCAAGGCCGCTTACA

Supplemental Table S1. Primer sequences used for RT-qPCR and DNA-qPCR.

ABCB1 overexpression as target to combat paclitaxel resistance

Cell line	IC ₅₀ Paclitaxel (nM) ± SEM	Paclitaxel resistance-factor	IC ₅₀ gemcitabine (nM) ± SEM	Gemcitabine resistance factor
Patu-T CTR	2.23 ± 0.67	NA	8.33 ± 1.42	NA
Patu-T PR	1725 ± 186	774	2.10 ± 0.16	-
Patu-T GR	0.92 ± 0.58	-	> 12000	1440
<hr/>				
Suit-2.007 CTR	16.46 ± 6.42	NA	7.09 ± 2.19	NA
Suit-2.007 PR	1665 ± 245	101	9.78 ± 1.40	-
Suit-2.007 GR	0.53 ± 0.50	-	> 3000	423
<hr/>				
Suit-2.028 CTR	5.17 ± 0.46	NA	3.86 ± 0.28	NA
Suit-2.028 PR	3096.5 ± 744	599	1.65 ± 0.35	-
Suit-2.028 GR	21 ± 5.2	-	711 ± 116	184

Supplemental Table S2. IC₅₀ values of the established resistant cell lines and CTR and the respective Resistance factors.

Chapter 2

Upregulated RNAs in two PR models		Upregulated proteins in two PR models
HNRNPA1P9	DMTF1	ABCB1
ABCB1	ABCB4	EEF1A2
AC003991.3	ADAM22	FAM83H
CROT	MAPK15	SRI
CTD-2369P2.8	TP53TG1_2	SRXN1
STEAP4	TP53TG1_1	TBC1D13
RP11-354M1.2	FDPSP7	TMEM120A
GRM3	CTB-167B5.1	
HOXC13-AS	MDH2	
AC005522.7	CACNA2D1	
AC005076.5	SEMA3C	
AC034228.4	POR	
DBF4	TMEM243	
KIAA1324L	AC005559.3	
SRI	HLA-DQB1-AS1	
RP11-66B24.9	RP11-701H16.4	
RP11-709A23.2	AP001610.5	


Supplemental Table S3. List of upregulated RNAs and proteins shared between Patu-T PR and Suit-2.028 PR cells. Common hits in RNA-seq and proteomics data are indicated in bold.

ABCB1 overexpression as target to combat paclitaxel resistance


Name	Pathway	Target	Literature connection ABCB1
AZ 3146	Cytoskeletal Signaling	Mps1	no
Nazartinib (EGF816. NVS-816)	Angiogenesis	EGFR	no
Derazantinib (ARQ-087)	Protein sine Kinase	Tyro-FGFR	no
Naquotinib (ASP8273)	Angiogenesis	EGFR	no
Apatinib	Protein sine Kinase	Tyro-VEGFR.c-RET	Yes (Mi Y. 2010)
SGI-1776 free base	JAK/STAT	Pim	Yes (Mumenthaler S. 2010)

Supplemental Table S4. Selected hits from KI-screen.


Chapter 2




Supplementary Figure S1. Correlation plots and Principal component analysis (PCA) of RNA-seq and proteomics data. **(A)** Correlation plots show good correlation for biological replicates within the same cell line, and no or poor correlation among different cell lines. **(B)** PCA analysis for RNA-seq and proteomics data. Plots show separation of CTR, GR, and PR samples in RNA-seq (top) and proteomics (bottom) data sets




Supplementary Figure S2. Volcano plots of differentially expressed genes/proteins for PR vs CTR cells. Grey = not significant (NS); green = only log2FC > 2 or < -2; blue = only p-value < 0.05; red = p-value < 0.05 and log2FC > 2 or < -2. The latter criteria identified 15198 and 15621 differentially expressed RNAs and 5309 and 5231 differentially expressed proteins in Patu-T and Suit-2.028, respectively.




Supplementary Figure S3. Upregulation of ABC transporters in PR cells. Venn diagram showing upregulated ABC transporters in PR models.



Supplementary Figure S4. Uncropped Western blot membranes for Patu-T, Suit-2.028 and Suit-2.007 CTR, PR, and GR cells stained for ABCB1 and B-actin. One biological replicate of western blot is shown for each cell line. Each sample was collected from untreated cells.




Supplementary Figure S5. ABCB1 upregulation correlates with poor survival. **(A)** Kaplan-Meier curves of the patients that underwent surgery, grouped according ABCB1 expression, showing a trend towards reduced probability of survival in case of high (red) vs. low (blue) expression. **(B)** Clinicopathological characteristics and correlation with mean overall survival (OS) of the PDAC patients.




Supplementary Figure S6. Verapamil mono treatment does not affect PR cell proliferation and verapamil does not sensitize to gemcitabine. **(A)** Representative growth curves of 3 PR cell lines (red) exposed to verapamil concentration ranges, relative to DMSO control. Mean and SD of triplicates is shown. The experiment was repeated 3 times. **(B)** Representative growth curves showing effect of 5 μM or 10 μM Verapamil on increasing

concentrations of gemcitabine for CTR (left) or GR (right) PDAC cells. Mean and SD of triplicates is shown. The experiment was repeated 2 times.



Supplementary Figure S7. KI screen validation in Suit-2.007 and Suit-2.028 PR cells. **(A)** Impact on cell proliferation. Selected KIs from KI library screen were tested at 1 μ M in absence (black bars) or presence (red bars) of 0.1 μ M paclitaxel (PTX). Proliferation was assessed after 72 hours of treatment. Dotted line represents the DMSO control (100%). Experiments were performed in technical duplicates. Mean and SD of three independent experiments is shown. Ordinary one-way ANOVA was performed, followed by Šídák's multiple comparisons test. **, $p < 0.005$; ****, $p < 0.0001$. **(B)** Impact on Hoechst exclusion. Selected KIs from KI library screen were tested for their ability to prevent Hoechst exclusion in PR cells. Relative Hoechst signal intensity for the indicated treatments versus DMSO is shown. Mean and SD of 3 independent experiments performed in triplicates is shown. Ordinary one-way ANOVA with Dunnett's post hoc test was used. *, $p < 0.05$; **, $p < 0.005$; ****, $p < 0.0001$.



Supplementary Figure S8. KI treatment of PR cells does not decrease ABCB1 expression to level of CTR cells. Gene expression of ABCB1 and GAPDH in PR cells after 48h of treatment with 1 μ M of the indicated KI, measured by RT-qPCR and calculated as fold change ($2^{-\Delta\Delta Ct}$ compared to the DMSO control). Untreated CTR sample was included as negative control for ABCB1 expression (blue). Bars, mean of triplicates. 1 experiment was performed.

Chapter 2
